H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD – Research Report) today and set a price target of $13.00. The company’s shares closed last Thursday at $4.19, close to its 52-week low of $3.53.
According to TipRanks.com, White is a 4-star analyst with an average return of 7.8% and a 36.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.
Celyad has an analyst consensus of Moderate Buy.
Celyad’s market cap is currently $92.64M and has a P/E ratio of -3.30. The company has a Price to Book ratio of 4.55.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Read More on CYAD:
- H.C. Wainwright Reiterates Their Buy Rating on Alpine Immune Sciences (ALPN)
- Analysts Have Conflicting Sentiments on These Technology Companies: Entegris (ENTG) and Microsoft (MSFT)
- ITC Bans Roku’s Product Imports; Shares Hit a New All Year Low
- Avis Budget Stock: Set For Downside Mean Reversion
- Berenberg Bank Reaffirms Their Buy Rating on PTC (PTC)